The US Food and Drug Administration (FDA) has expanded the approval of fam-trastuzumab–deruxtecan-nxki (Enhertu; AstraZeneca and Daiichi Sankyo, Inc) to adults with unresectable or metastatic as well as adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who had received a prior trastuzumab-based regimen. This approval provides a new treatment option for patients with limited options.
The US Food and Drug Administration has expanded the approval of fam-trastuzumab–deruxtecan-nxki to adults with unresectable or metastaticas well as adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who had received a prior trastuzumab-based regimen.
The most common adverse reactions occurring in at least 20% of patients included decreased white blood cell count, hemoglobin, lymphocyte count, and neutrophil count, as well as nausea, fatigue, platelet count, vomiting, alopecia,Sharon Worcester, MA, is an award-winning medical journalist based in Birmingham, Alabama, writing for Medscape, MDedge and other affiliate sites. She currently covers oncology, but she has also written on a variety of other medical specialties and healthcare topics.
FDA Approval Fam-Trastuzumab-Deruxtecan-Nxki HER2-Positive Gastric Cancer Treatment Option
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
FDA Expands Enhertu Indication to HER2-Positive Solid TumorsThe move from the FDA marks the first tumor-agnostic approval of a HER2-directed therapy and antibody drug conjugate.
Les mer »
FDA Expands Approval of Treatment for Generalized Pustular PsoriasisSpesolimab-sbzo was initially approved in 2022 for treating flares of generalized pustular psoriasis in adults.
Les mer »
FDA Expands Indications for Bempedoic Acid in CVD PreventionBempedoic acid and bempedoic–ezetimibe are now indicated to prevent myocardial infarction and cardiovascular procedures in both primary- and secondary-prevention patients regardless of statin use.
Les mer »
FDA Expands Indications for Bempedoic Acid to Prevent Heart AttacksThe US Food and Drug Administration (FDA) has expanded the indications for bempedoic acid (Nexletol) and bempedoic acid plus ezetimibe combination (Nexlizet) to prevent heart attacks and cardiovascular procedures in both primary- and secondary-prevention patients regardless of statin use.
Les mer »
New Drug Regimen for Pancreatic Cancer Receives FDA ApprovalA new drug regimen for certain types of pancreatic cancer recently received approval from the U.S. Food and Drug Administration (FDA) — the first new medication in nearly a decade.
Les mer »
Supreme Court to rule on FDA approval of abortion drug mifepristoneThe U.S. Supreme Court will hear oral arguments Tuesday about the federal government's approval process for the drug mifepristone, used to terminate pregnancies.
Les mer »